Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
|Articles|February 2, 2015

NJ Adopts ERT Solution for Suicide Monitoring in Students

ERT, a leading provider of technology solutions and services that increase the reliability and efficiency of high-quality patient data collection, today announced that its electronic Suicide Risk Assessment (SRA) system – AVERT® – will be implemented by Rutgers University

ERT, a provider of technology solutions and services that increase the reliability and efficiency of high-quality patient data collection, announced that its electronic Suicide Risk Assessment (SRA) system – AVERT® – will be implemented by Rutgers University Behavioral Health Care (UBHC) as part of the New Jersey Youth Suicide Prevention Project (NJYSPP).  Beginning this semester, AVERT will be used to identify and routinely assess suicide risk among high school and college students in six targeted NJ counties (Bergen, Camden, Hudson, Passaic, Middlesex and Monmouth). Suicide is the second leading cause of death among 15 to 24 year olds in the United States (2012).  Funded by a grant administered by the Substance Abuse and Mental Health Services Administration, the NJYSPP is a comprehensive approach to youth suicide prevention, which provides gatekeepers in the counties with best-practice and evidence-based trainings in suicide prevention, intervention, and postvention at no charge.  By using the AVERT self-assessment system, the NJYSPP’s objective is to help school-based gatekeepers proactively identify at-risk students and more efficiently refer them to trained mental health professionals in their community. Read the full release here.


Related to this article

What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.